Sabby Management’s Regulus Therapeutics RGLS Stock Holding History

Sabby Management’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-92	Closed	-$3.63M	–	324
2016 Q3	$3.63M	Sell	92 -4	-4%	-$1.65K	0.14%	90
2016 Q2	$3.34M	Sell	96 -2	-2%	-$1.43K	0.17%	75
2016 Q1	$8.11M	Sell	98 -2	-2%	-$1.59K	0.41%	31
2015 Q4	$10.4M	Sell	100 -1	-1%	-$1K	0.57%	32
2015 Q3	$7.93M	Buy	101 +3	+3%	+$3.08K	0.33%	48
2015 Q2	$12.9M	Hold	98	–	–	0.47%	44
2015 Q1	$20M	Buy	98 +6	+7%	+$13K	0.83%	28
2014 Q4	$2.5M	Buy	+92	New	+$164K	0.08%	109

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Sabby Management's RGLS Position: Q3 2016 in Review

Sabby Management sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 410 shares — an estimated $169K sold.

Sabby Management first reported a position in RGLS in Q4 2014 and held it in 7 quarters. The position peaked at $5.65M in Q4 2014. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

Sabby Management reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 410 Regulus Therapeutics shares in Q3 2016, an estimated $169K.
Sabby Management first reported a position in Regulus Therapeutics in Q4 2014 and held it in 7 quarters.
Sabby Management's Regulus Therapeutics position peaked at $5.65M in Q4 2014.
83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.